Spokane woman gets back her 'normal life' from newly approved Parkinson's disease treatment
After being diagnosed with Parkinson's disease at 50, Janice Hall felt her tremors get worse. Three years after being diagnosed she could "feel a kind of fluttering" that her medication could not stop ...
FDA approves Vyalev for advanced Parkinson's disease
The U.S. Food and Drug Administration has approved AbbVie's Vyalev (foscarbidopa and foslevodopa) for adults living with ...
HealthDay on MSN1d
FDA Approves Vyalev for Advanced Parkinson Disease
The U.S. Food and Drug Administration has approved Vyalev (foscarbidopa and foslevodopa) for adults living with advanced ...
Ask Dr James: What can I do about my restless legs?
Just over five years ago I was diagnosed with restless legs syndrome – my symptoms were apparently ‘typical’. The neurologist ...
PharmiWeb2d
Global Parkinson’s Disease Market Set for USD 6.7 Billion Valuation, Powered by a 5.1% CAGR, from 2024 to 2034
Parkinson’s Disease Therapeutic MarketThe Global Parkinson’s Disease Industry is poised to achieve an estimated worth of USD 5.41 Billion, reflecting a notable increase from the USD 4.82 Billion ...
McKnight's Long-Term Care News4d
A new treatment option gets FDA approval for adults with advanced Parkinson’s disease
The US Food and Drug Administration has approved VYALEV, a groundbreaking therapy developed by AbbVie to treat adults with ...
Pharmabiz5d
AbbVie’s Vyalev receives US FDA approval to treat adults living with advanced Parkinson's disease
North Chicago, Illinois Saturday, October 19, 2024, 12:00 Hrs [IST] ...
Medscape5d
FDA OKs Novel Levodopa-Based Continuous Sub-Q Regimen for Parkinson’s
Vyalev (AbbVie) is the first and only subcutaneous 24-hour continuous infusion of levodopa-based therapy to address motor fluctuations in advanced Parkinson’s disease.
Yahoo Finance5d
FDA Approves AbbVie's VYALEV as First 24-Hour Levodopa Infusion for Advanced Parkinson's
The first levodopa-based treatment for motor fluctuations in people with advanced Parkinson's disease, VYALEVa subcutaneous ...
GlobalData on MSN5d
FDA approves AbbVie’s VYALEV for advanced Parkinson’s treatment
The US Food and Drug Administration (FDA) has approved AbbVie's VYALEV (foscarbidopa and foslevodopa) to treat motor ...
BioWorld6d
After delays, Abbvie wins FDA approval for Parkinson’s treatment
With two complete response letters in the rearview mirror, Abbvie Inc.’s Vyalev (foscarbidopa/foslevodopa) has been approved by the U.S. FDA for treating Parkinson’s disease. The drug is the first ...
FDA Approves AbbVie's Parkinson's Treatment, Medicare Coverage Expected Next Year
Vyalev (foscarbidopa and foslevodopa) as the first and only subcutaneous 24-hour infusion of levodopa-based therapy for motor ...